For the Inventor, By the Inventor

Enter assignee name

Raritan, NJ, United States of America

Ortho-Mcneil Pharmaceutical Corp.

USPTO Granted Patents = 363

% Expired Patents = 22.0

CIPO Patents = 13

EPO Patents = 10

Trademarks = 1

Forward Citations = 3,222

Loading Chart...

Loading Chart...

446 inventors (with patents filed for the assignee):

Bruce E Maryanoff (29 out of 101 patents)

Allen B Reitz (22 out of 101 patents)

Carlos Plata-Salaman (17 out of 19 patents)

4. William V Murray (16 out of 49 patents)

5. Andrew Lawrence Darrow (16 out of 16 patents)

6. Jianmei Wei (15 out of 39 patents)

7. Michael Hawkins (15 out of 30 patents)

8. J Guy Breitenbucher (15 out of 41 patents)

9. Barbara A Pio (15 out of 48 patents)

10. James Patrick Edwards (15 out of 165 patents)

11. William Joel Hoekstra (15 out of 81 patents)

12. Michael Nicholas Greco (14 out of 46 patents)

13. Zhihua Sui (14 out of 108 patents)

14. Steven P Meduna (14 out of 31 patents)

15. Hui Cai (14 out of 21 patents)

Core Competencies:

Phosphonic Acid Compounds

Serine Protease Inhibitors

Melanocortin Receptor Modulators

Combination Therapy

Cytotoxic T Lymphocytes

Peptide Therapies

Vasopressin Antagonists

Kinase Inhibitors

Neuroprotective Peptides

Erythropoietin Mimetics

Thrombin Receptor Antagonists

Diabetes Treatment

363 patents: Sort by Forward Citations

1. 8609888 - Phosphonic acid compounds as inhibitors of serine proteases (2013-12-17),

2. 8501791 - 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators (2013-08-06),

3. 8497373 - Phosphonic acid compounds as inhibitors of serine proteases (2013-07-30),

4. 8304430 - Phosphonic acid compounds as inhibitors of serine proteases (2012-11-06),

5. 8278268 - Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators (2012-10-02),

6. 8247599 - Phosphonic acid compounds as inhibitors of serine proteases (2012-08-21),

7. 8212039 - Phosphonic acid compounds as inhibitors of serine proteases (2012-07-03),

8. 8207338 - Phosphonic acid compounds as inhibitors of serine proteases (2012-06-26),

9. 8198440 - Phosphonic acid compounds as inhibitors of serine proteases (2012-06-12),

10. 8183213 - Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators (2012-05-22),

11. 8178673 - Phosphonic acid compounds as inhibitors of serine proteases (2012-05-15),

12. 8133972 - IgE antigenic peptides (2012-03-13),

13. 8133728 - Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease (2012-03-13),

14. 8133726 - Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease (2012-03-13),

15. 8106236 - Triaryl compounds and derivates thereof (2012-01-31),

Company Overview

Ortho-McNeil Pharmaceutical Corp., based in Raritan, NJ, specializes in the development and manufacturing of innovative pharmaceutical compounds. The company focuses on a range of therapeutic areas, employing advanced technologies such as phosphonic acid compounds and serine protease inhibitors. Their research encompasses diverse topics, including melanocortin receptor modulators, combination therapies, and peptide therapies, aimed at addressing complex medical conditions and improving patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

363 Patents

#3 in Raritan, NJ

#66 in New Jersey

#1,259 in US

#2,534 in the World

Raritan, NJ, United States of America

Ortho-Mcneil Pharmaceutical Corp.

Forward Citations = 3,222

446 inventors:

Bruce E Maryanoff (29 out of 101 patents)

Allen B Reitz (22 out of 101 patents)

Carlos Plata-Salaman (17 out of 19 patents)

4. William V Murray (16 out of 49 patents)

5. Andrew Lawrence Darrow (16 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ortho-Mcneil Pharmaceutical Corp.. Retrieved from https://idiyas.com/company/ortho-mcneil-pharmaceutical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…